The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Trends in Receipt of Buprenorphine and Naltrexone for Opioid Use Disorder Among Adolescents and Young Adults, 2001-2014
Open accessAbstract
Importance: Opioid use disorder (OUD) frequently begins in adolescence and young adulthood. Intervening early with pharmacotherapy is recommended by major professional organizations. No prior national studies have examined the extent to which adolescents and young adults (collectively termed youth) with OUD receive pharmacotherapy. Objective: To identify time trends and disparities in receipt of buprenorphine and naltrexone among youth with OUD in the United States. Design, Setting, and Participants: A retrospective cohort study was conducted using deidentified data from a national commercial insurance database. Enrollment and complete health insurance claims of 9.7 million youth, aged 13 to 25 years were analyzed, identifying individuals who received a diagnosis of OUD between January 1, 2001, and June 30, 2014, with final follow-up date December 31, 2014. Analysis was conducted from April 25 to December 31, 2016. Time trends were identified and multivariable logistic regression was used to determine sociodemographic factors associated with medication receipt. Exposures: Sex, age, race/ethnicity, neighborhood education and poverty levels, geographic region, census region, and year of diagnosis. Main Outcomes and Measures: Dispensing of a medication (buprenorphine or naltrexone) within 6 months of first receiving an OUD diagnosis. Results: Among 20 822 youth diagnosed with OUD (0.2% of the 9.7 million sample), 13 698 (65.8%) were male and 17 119 (82.2%) were non-Hispanic white. Mean (SD) age was 21.0 (2.5) years at the first observed diagnosis. The diagnosis rate of OUD increased nearly 6-fold from 2001 to 2014 (from 0.26 per 100 000 person-years to 1.51 per 100 000 person-years). Overall, 5580 (26.8%) youth were dispensed a medication within 6 months of diagnosis, with 4976 (89.2%) of medication-treated youth receiving buprenorphine and 604 (10.8%) receiving naltrexone. Medication receipt increased more than 10-fold, from 3.0% in 2002 (when buprenorphine was introduced) to 31.8% in 2009, but declined in subsequent years (27.5% in 2014). In multivariable analyses, younger individuals were less likely to receive medications, with adjusted probability for age 13 to 15 years, 1.4% (95% CI, 0.4%-2.3%); 16 to 17 years, 9.7% (95% CI, 8.4%-11.1%); 18 to 20 years, 22.0% (95% CI, 21.0%-23.0%); and 21 to 25 years, 30.5% (95% CI, 30.0%-31.5%) (P < .001 for difference). Females (7124 [20.3%]) were less likely than males (13 698 [24.4%]) to receive medications (P < .001), as were non-Hispanic black (105 [14.8%]) and Hispanic (1165 [20.0%]) youth compared with non-Hispanic white (17 119 [23.1%]) youth (P < .001). Conclusions and Relevance: In this first national study of buprenorphine and naltrexone receipt among youth, dispensing increased over time. Nonetheless, only 1 in 4 commercially insured youth with OUD received pharmacotherapy, and disparities based on sex, age, and race/ethnicity were observed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Increases in drug and opioid overdose deaths — United States, 2000–2014
Rudd, R. A., Aleshire, N., Zibbell, J. E., & Gladden, R. M. (2016) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6450a3 · Cited by 1,859
Johnston, L., Miech, R., & O'Malley, P. (2020) · doi:10.3998/2027.42/162579 · Cited by 1,611
Trends in Opioid Analgesic Abuse and Mortality in the United States
Dart, R. C., Surratt, H. L., Cicero, T. J., Parrino, M. W., Severtson, S. G., Bucher-Bartelson, B., & Green, J. L. (2015) · New England Journal of Medicine · doi:10.1056/nejmsa1406143 · Cited by 1,137
Krieger, N., Chen, J. T., Waterman, P. D., Rehkopf, D. H., & Subramanian, S. V. (2003) · American Journal of Public Health · doi:10.2105/ajph.93.10.1655 · Cited by 711
Pharmaceutical Overdose Deaths, United States, 2010
Jones, C. M., Mack, K. A., & Paulozzi, L. J. (2013) · JAMA · doi:10.1001/jama.2013.272 · Cited by 678
Kampman, K., & Jarvis, M. (2015) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000166 · Cited by 678
National and state treatment need and capacity for opioid agonist medication-assisted treatment
Jones, C. M., Campopiano, M., Baldwin, G., & McCance-Katz, E. (2015) · American Journal of Public Health · doi:10.2105/ajph.2015.302664 · Cited by 668
Fudala, P. J., Bridge, T. P., Herbert, S., Williford, W. O., Chiang, C. N., Jones, K., Collins, J., Raisch, D., Casadonte, P., Goldsmith, R. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022164 · Cited by 577
Krupitsky, E., Nunes, E. V., Ling, W., Illeperuma, A., Gastfriend, D. R., & Silverman, B. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60358-9 · Cited by 555
Zibbell, J. E., Iqbal, K., Patel, R. C., Suryaprasad, A. G., Sanders, K. J., Moore-Moravian, L., Serrecchia, J., Blankenship, S., Ward, J. W., & Holtzman, D. J. (2015) · PubMed Central · Cited by 507
Women and Addiction: The Importance of Gender Issues in Substance Abuse Research
Tuchman, E. (2010) · Journal of Addictive Diseases · doi:10.1080/10550881003684582 · Cited by 403
Geographic and Specialty Distribution of US Physicians Trained to Treat Opioid Use Disorder
Rosenblatt, R. A., Andrilla, C. H. A., Catlin, M., & Larson, E. H. (2015) · The Annals of Family Medicine · doi:10.1370/afm.1735 · Cited by 380
Woody, G. E., Poole, S. A., Subramaniam, G., Dugosh, K., Bogenschutz, M., Abbott, P., Patkar, A., Publicker, M., McCain, K., Potter, J. S., et al. (2008) · JAMA · doi:10.1001/jama.2008.574 · Cited by 361
Substance Use Screening, Brief Intervention, and Referral to Treatment
Levy, S. J. L., Williams, J. F., COMMITTEE ON SUBSTANCE USE AND PREVENTION, Ryan, S. A., Gonzalez, P. K., Patrick, S. W., Quigley, J., Siqueira, L., Smith, V. C., & Walker, L. R. (2016) · Pediatrics · doi:10.1542/peds.2016-1211 · Cited by 347
Drug-poisoning Deaths Involving Opioid Analgesics: United States, 1999-2011.
Chen, L. H., Hedegaard, H. B., & Warner, M. (2014) · PubMed · Cited by 295
Gaither, J. R., Leventhal, J. M., Ryan, S. A., & Camenga, D. R. (2016) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2016.2154 · Cited by 275
Alford, D. P., LaBelle, C. T., Kretsch, N., Bergeron, A., Winter, M., Botticelli, M., & Samet, J. H. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.541 · Cited by 267
Self-citationUse of Geocoding and Surname Analysis to Estimate Race and Ethnicity
Fiscella, K., & Fremont, A. M. (2006) · Health Services Research · doi:10.1111/j.1475-6773.2006.00551.x · Cited by 261
Alegria, M., Carson, N. J., Goncalves, M., & Keefe, K. (2011) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2010.10.005 · Cited by 229 · cited 1×
“Prior studies have shown that poorer access to substance use treatment amongminorities is in part explained by disparities in health insurance coverage.(34,41) However, our results indicate that, even with coverage, non-Hispanic black and Hispanic youth are less likely thannon-Hispanicwhite youth to receivemedications…”
LaBelle, C. T., Han, S. C., Bergeron, A., & Samet, J. H. (2016) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2015.06.010 · Cited by 228
Self-citationMedication-Assisted Treatment of Adolescents With Opioid Use Disorders
COMMITTEE ON SUBSTANCE USE AND PREVENTION, Ryan, S. A., Gonzalez, P. K., Patrick, S. W., Quigley, J., Siqueira, L., & Walker, L. R. (2016) · Pediatrics · doi:10.1542/peds.2016-1893 · Cited by 223
Marsch, L. A., Bickel, W. K., Badger, G. J., Stothart, M. E., Quesnel, K. J., Stanger, C., & Brooklyn, J. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.10.1157 · Cited by 205
Cummings, J. R., Wen, H., Ko, M., & Druss, B. G. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.3575 · Cited by 200
Substance Use Screening, Brief Intervention, and Referral to Treatment for Pediatricians
Levy, S. J. L., Kokotailo, P. K., & Committee on Substance Abuse (2011) · Pediatrics · doi:10.1542/peds.2011-1754 · Cited by 200
JAFFE, J. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00055-3 · Cited by 165
Dick, A. W., Pacula, R. L., Gordon, A. J., Sorbero, M., Burns, R. M., Leslie, D., & Stein, B. D. (2015) · Health Affairs · doi:10.1377/hlthaff.2014.1205 · Cited by 159
Lê Cook, B., & Alegría, M. (2011) · Psychiatric Services · doi:10.1176/appi.ps.62.11.1273 · Cited by 158
The Affordable Care Act and Insurance Coverage for Young Adults
Sommers, B. D., & Kronick, R. G. (2012) · JAMA · doi:10.1001/jama.307.9.913 · Cited by 150
Stein, B. D., Pacula, R. L., Gordon, A. J., Burns, R. M., LESLIE, D. L., Sorbero, M., Bauhoff, S., Mandell, T. W., & Dick, A. W. (2015) · Milbank Quarterly · doi:10.1111/1468-0009.12137 · Cited by 116
Physician Education in Addiction Medicine
Wood, E., Samet, J. H., & Volkow, N. D. (2013) · JAMA · doi:10.1001/jama.2013.280377 · Cited by 106
Self-citationMarsch, L. A., Moore, S. K., Borodovsky, J. T., Solhkhah, R., Badger, G. J., Semino, S. J., Jarrett, K., Condon, K. A. D., Rossettie, K., Vincent, P., et al. (2016) · Addiction · doi:10.1111/add.13363 · Cited by 101
Stein, B. D., Gordon, A. J., Sorbero, M., Dick, A. W., Schuster, J., & Farmer, C. M. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.10.016 · Cited by 98
Saloner, B. K., Carson, N. J., & Cook, B. L. (2014) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2014.01.002 · Cited by 71
Lee, J. D., Nunes, E. V., Novo, P., Bailey, G. L., Brigham, G. S., Cohen, A. J., Fishman, M. J., Ling, W. W., Lindblad, R., Shmueli‐Blumberg, D., et al. (2016) · Contemporary Clinical Trials · doi:10.1016/j.cct.2016.08.004 · Cited by 67
Adolescent Substance Abuse and Mental Health: Problem Co-Occurrence and Access to Services
Winstanley, E. L., Steinwachs, D. M., Stitzer, M. L., & Fishman, M. J. (2012) · Journal of Child & Adolescent Substance Abuse · doi:10.1080/1067828x.2012.709453 · Cited by 42
National Trends in Adolescent Substance Use Disorders and Treatment Availability: 2003–2010
Mericle, A. A., Arria, A. M., Meyers, K., Cacciola, J., Winters, K. C., & Kirby, K. C. (2015) · Journal of Child & Adolescent Substance Abuse · doi:10.1080/1067828x.2013.829008 · Cited by 34
How the paediatric workforce can address the opioid crisis
Hadland, S. E., Wood, E., & Levy, S. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31573-2 · Cited by 28
Self-citationHealth Insurance Enrollment and Availability of Medications for Substance Use Disorders
Abraham, A. J., Rieckmann, T. R., Andrews, C. M., & Jayawardhana, J. (2016) · Psychiatric Services · doi:10.1176/appi.ps.201500470 · Cited by 8
Cited by
Comparative effectiveness of different treatment pathways for opioid use disorder.
Wakeman, S. E., Larochelle, M. R., Ameli, O., Chaisson, C. E., McPheeters, J. T., Crown, W. H., Azocar, F., & Sanghavi, D. M. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.20622 · Cited by 995
Self-citationManagement of opioid use disorder in the USA: present status and future directions
Blanco, C., & Volkow, N. D. (2019) · The Lancet · doi:10.1016/s0140-6736(18)33078-2 · Cited by 407
Patient-Reported Experiences of Discrimination in the US Health Care System
Nong, P., Raj, M., Creary, M., Kardia, S. L. R., & Platt, J. E. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.29650 · Cited by 255
Hogue, A., Becker, S. J., Wenzel, K., Henderson, C. E., Bobek, M., Levy, S., & Fishman, M. (2021) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2021.108402 · Cited by 101
Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity
Toce, M. S., Chai, P. R., Burns, M. M., & Boyer, E. W. (2018) · Journal of Medical Toxicology · doi:10.1007/s13181-018-0685-1 · Cited by 90
Metadata
- Authors
- Hadland, S. E., Wharam, J. F., Schuster, M. A., Zhang, F., Samet, J. H., & Larochelle, M. R.
- Venue
- JAMA Pediatrics
- Publisher
- American Medical Association (AMA)
- Published
- 2017-08-01
- Volume
- 171
- Issue
- 8
- Pages
- 747
- ISSN
- 1072-4710 (ISSN-L)
- 2168-6203
- OpenAlex
- W2626978912
- Cited by
- 294
- References
- 38
- FWCI
- 20.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.